Document:

Exhibit 10.5

THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE UNITED STATES  SECURITIES AND
EXCHANGE  COMMISSION OR THE  SECURITIES  COMMISSION OF ANY STATE  PURSUANT TO AN
EXEMPTION FROM REGISTRATION  UNDER REGULATION D PROMULGATED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE "ACT").  THIS WARRANT SHALL NOT CONSTITUTE AN OFFER
TO SELL NOR A SOLICITATION OF AN OFFER TO BUY THE SECURITIES IN ANY JURISDICTION
IN WHICH  SUCH OFFER OR  SOLICITATION  WOULD BE  UNLAWFUL.  THE  SECURITIES  ARE
"RESTRICTED" AND MAY NOT BE RESOLD OR TRANSFERRED  EXCEPT AS PERMITTED UNDER THE
ACT PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.

                          COMMON STOCK PURCHASE WARRANT

     To Purchase Shares of $____ Par Value Common Stock ("Common Stock") of

                             No. [W-__ ] [ ] Shares

                                BIONUTRICS, INC.

         THIS CERTIFIES  that, for value  received,  ___________________________
(the  "PURCHASER"  or "HOLDER")  is entitled,  upon the terms and subject to the
conditions hereinafter set forth, at any time on or after the date hereof and on
or prior to 5:00 p.m.  New York City Time on the date that is three  years after
the date hereof (the "TERMINATION  DATE"), but not thereafter,  to subscribe for
and purchase  from  Bionutrics,  Inc.,  a Nevada  corporation  (the  "COMPANY"),
________________  [a number of shares of Common Stock equal to 50% of the number
of shares  of Common  Stock (i) into  which the Notes  purchased  by Holder  are
convertible or (ii) into which the Company  preferred  shares obtained by Holder
upon conversion of Notes is convertible]  (the "WARRANT  SHARES") at an Exercise
Price equal to the lesser of $5.50 per share or the price per share paid by cash
investors on the  Qualified  Equity  Financing  (as  adjusted  from time to time
pursuant to the terms hereof, the "EXERCISE PRICE").  The Exercise Price and the
number of shares  for which the  Warrant  is  exercisable  shall be  subject  to
adjustment as provided herein. This Warrant is being issued together Convertible
Promissory  Notes dated as of September  __, 2005 (the  "NOTES"),  issued by the
Company to  Holder.  This  Warrant  is being  issued  pursuant  to  Subscription
Agreement dated September __, 2005 (the "SUBSCRIPTION AGREEMENT"),  entered into
between  the Company and the  Purchaser.  Capitalized  terms used herein and not
otherwise  defined shall have the meaning  ascribed  thereto in the Notes or the
Subscription Agreement.

1.       TITLE OF  WARRANT.  Prior  to the  expiration  hereof  and  subject  to
         compliance with applicable  laws, this Warrant and all rights hereunder
         are  transferable,  in whole or in part, at the office or agency of the
         Company by the Holder hereof in person or by duly authorized  attorney,
         upon surrender of this Warrant  together with (a) the  Assignment  Form
         annexed  hereto  properly  endorsed,  and (b) any  other  documentation
         reasonably  necessary to satisfy the Company  that such  transfer is in
         compliance with all applicable securities laws. The term "Holder" shall
         refer to the Purchaser or any subsequent transferee of this Warrant.

2.       AUTHORIZATION  OF  SHARES.  The  Company  covenants  that all shares of
         Common   Stock  which  may  be  issued  upon  the  exercise  of  rights
         represented  by  this  Warrant  will,   upon  exercise  of  the  rights
         represented  by this Warrant and payment of the  Exercise  Price as set
         forth herein will be duly  authorized,  validly issued,  fully paid and
         nonassessable and free from all taxes, liens and charges

<PAGE>

         (other  than  liens  created  by the  Holder)  in  respect of the issue
         thereof  (other  than  taxes  in  respect  of  any  transfer  occurring
         contemporaneously with such issue or otherwise specified herein).

3.       Exercise of Warrant.

(a)      The Holder may exercise this Warrant,  in whole or in part, at any time
         and from time to time,  by  delivering to the offices of the Company or
         any transfer  agent for the Common Stock this Warrant,  together with a
         Notice of Exercise in the form annexed hereto  specifying the number of
         Warrant  Shares with respect to which this Warrant is being  exercised,
         together  with  payment in cash to the  Company of the  Exercise  Price
         therefor.

         In the event that the Warrant is not  exercised in full,  the number of
         Warrant  Shares shall be reduced by the number of such  Warrant  Shares
         for  which  this  Warrant  is  exercised  and/or  surrendered,  and the
         Company,  if requested by Holder and at the  Company's  expense,  shall
         within four (4) Trading  Days (as defined  below)  issue and deliver to
         the Holder a new  Warrant of like tenor in the name of the Holder or as
         the Holder (upon payment by Holder of any  applicable  transfer  taxes)
         may request, reflecting such adjusted Warrant Shares.

         Certificates  for shares of Common Stock  purchased  hereunder shall be
         delivered to the Holder  hereof within three (3) Trading Days after the
         date on which this Warrant shall have been exercised as aforesaid.  The
         Holder may  withdraw  its Notice of Exercise at any time if the Company
         fails to timely  deliver  the  relevant  certificates  to the Holder as
         provided in this  Agreement.  A Notice of Exercise shall be deemed sent
         on the date of delivery if delivered  before 5:00 p.m. New York Time on
         such date, or the day following such date if delivered  after 5:00 p.m.
         New York Time;  provided that the Company is only  obligated to deliver
         Warrant Shares  against  delivery of the Exercise Price from the holder
         hereof and surrender of this Warrant (or appropriate  affidavit  and/or
         indemnity in lieu thereof).

         In lieu of delivering  physical  certificates  representing the Warrant
         Shares issuable upon conversion of this Warrant, provided the Company's
         transfer agent is participating in the Depository Trust Company ("DTC")
         Fast Automated  Securities  Transfer ("FAST") program,  upon request of
         the Holder,  the Company shall use commercially  reasonable  efforts to
         cause its transfer agent to electronically  transmit the Warrant Shares
         issuable upon  exercise to the Holder,  by crediting the account of the
         Holder's  prime  broker with DTC through its Deposit  Withdrawal  Agent
         Commission  ("DWAC")  system.  The time periods for delivery  described
         above  shall  apply to the  electronic  transmittals  through  the DWAC
         system.  The Company agrees to use commercially  reasonable  efforts to
         coordinate with DTC to accomplish this objective.

(b)      The term  "TRADING  DAY" means (x) if the Common Stock is not listed on
         the New York or American  Stock  Exchange but sale prices of the Common
         Stock are  reported  on Nasdaq  National  Market or  another  automated
         quotation  system,  a day on which trading is reported on the principal
         automated  quotation  system  on which  sales of the  Common  Stock are
         reported,  (y) if the  Common  Stock is  listed  on the New York  Stock
         Exchange  or the  American  Stock  Exchange,  a day on  which  there is
         trading on such stock exchange,  or (z) if the foregoing provisions are
         inapplicable,  a day on  which  quotations  are  reported  by  National
         Quotation Bureau Incorporated.

4.       No  Fractional   Shares  or  Scrip.  No  fractional   shares  or  scrip
         representing  fractional  shares  shall be issued upon the  exercise of
         this  Warrant.  In lieu of  issuance  of a  fractional  share  upon any
         exercise  hereunder,  the Company will either round up to nearest whole
         number of shares or pay the cash value of that fractional share,  which
         cash value shall be calculated on the basis of the

<PAGE>

         average  closing  price of the Common Stock during the five (5) Trading
         Days immediately preceding the date of exercise.

5.       Charges,  Taxes and Expenses.  Issuance of  certificates  for shares of
         Common Stock upon the  exercise of this  Warrant  shall be made without
         charge to the  Holder  hereof  for any issue or  transfer  tax or other
         incidental expense in respect of the issuance of such certificate,  all
         of which  taxes and  expenses  shall be paid by the  Company,  and such
         certificates  shall be issued in the name of the Holder of this Warrant
         or in such  name or  names as may be  directed  by the  Holder  of this
         Warrant;  PROVIDED,  HOWEVER, that in the event certificates for shares
         of Common  Stock are to be issued in a name  other than the name of the
         Holder of this  Warrant,  this  Warrant when  surrendered  for exercise
         shall be  accompanied  by the  Assignment  Form  attached  hereto  duly
         executed by the Holder hereof;  and PROVIDED FURTHER,  that the Company
         shall not be  required  to pay any tax or taxes which may be payable in
         respect  of any  transfer  involved  in  the  issuance  of any  Warrant
         certificates or any  certificates for the Warrant Shares other than the
         issuance of a Warrant  Certificate to the Holder in connection with the
         Holder's surrender of a Warrant Certificate upon the exercise of all or
         less than all of the Warrants evidenced thereby.

6.       CLOSING  OF  BOOKS.  Subject  to  applicable  law and the  rules of the
         principal market on which the Common Stock may from time to time trade,
         the Company will at no time close its  shareholder  books or records in
         any manner which interferes with the timely exercise of this Warrant.

7.       NO RIGHTS AS SHAREHOLDER UNTIL EXERCISE.  Subject to Section 12 of this
         Warrant and the provisions of any other written  agreement  between the
         Company and the Purchaser,  the Purchaser shall not be entitled to vote
         or receive  dividends or be deemed the holder of Warrant  Shares or any
         other securities of the Company that may at any time be issuable on the
         exercise hereof for any purpose, nor shall anything contained herein be
         construed to confer upon the Purchaser, as such, any of the rights of a
         stockholder  of the  Company or any right to vote for the  election  of
         directors or upon any matter  submitted to  stockholders at any meeting
         thereof,  or to  give  or  withhold  consent  to any  corporate  action
         (whether upon any recapitalization, issuance of stock, reclassification
         of stock,  change  of par  value,  or change of stock to no par  value,
         consolidation, merger, conveyance or otherwise) or to receive notice of
         meetings,  or to receive dividends or subscription  rights or otherwise
         until  the  Warrant  shall  have been  exercised  as  provided  herein.
         However,  at the  time of the  exercise  of this  Warrant  pursuant  to
         Section 3 hereof,  the Warrant Shares so purchased  hereunder  shall be
         deemed to be issued to such  Holder as the record  owner of such shares
         as of the close of  business  on the date on which this  Warrant  shall
         have been exercised.

8.       ASSIGNMENT AND TRANSFER OF WARRANT. This Warrant may be assigned by the
         surrender of this Warrant and the  Assignment  Form annexed hereto duly
         executed at the office of the  Company (or such other  office or agency
         of the Company or its  transfer  agent as the Company may  designate by
         notice in writing to the  registered  Holder  hereof at the  address of
         such Holder appearing on the books of the Company);  PROVIDED, HOWEVER,
         that this Warrant may not be resold or otherwise transferred except (i)
         in a  transaction  registered  under  the  Securities  Act of 1933,  as
         amended (the "Act"), or (ii) in a transaction pursuant to an exemption,
         if  available,   from  registration  under  the  Act  and  whereby,  if
         reasonably  requested by the Company,  an opinion of counsel reasonably
         satisfactory  to the Company is obtained by the Holder of this  Warrant
         to the effect that the transaction is so exempt.

9.       LOSS,  THEFT,  DESTRUCTION  OR  MUTILATION  OF WARRANT;  EXCHANGE.  The
         Company represents  warrants and covenants that (a) upon receipt by the
         Company of evidence and/or indemnity  reasonably  satisfactory to it of
         the loss,  theft,  destruction  or  mutilation  of any Warrant or stock
         certificate

<PAGE>

         representing  the  Warrant  Shares,  and in  case  of  loss,  theft  or
         destruction,  of indemnity reasonably  satisfactory to it, and (b) upon
         surrender and  cancellation  of such Warrant or stock  certificate,  if
         mutilated,  the  Company  will make and  deliver a new Warrant or stock
         certificate of like tenor and dated as of such cancellation, in lieu of
         this Warrant or stock  certificate,  without any charge therefor.  This
         Warrant is exchangeable  at any time for an equal  aggregate  number of
         Warrants  of  different  denominations,  as  requested  by  the  holder
         surrendering the same, or in such  denominations as may be requested by
         the Holder  following  determination  of the Exercise Price. No service
         charge  will be made for such  registration  or  transfer,  exchange or
         reissuance.

10.      SATURDAYS, SUNDAYS, HOLIDAYS, ETC. If the last or appointed day for the
         taking of any action or the expiration of any right required or granted
         herein shall be a Saturday, Sunday or a legal holiday, then such action
         may be taken or such right may be exercised on the next  succeeding day
         not a legal holiday.

11.      EFFECT OF CERTAIN  EVENTS.  If at any time  while  this  Warrant or any
         portion   thereof  is  outstanding  and  unexpired  there  shall  be  a
         transaction  (by  merger or  otherwise)  in which  more than 50% of the
         voting  power of the Company is disposed of  (collectively,  a "Sale or
         Merger  Transaction"),  the Holder of this Warrant shall have the right
         thereafter to purchase,  by exercise of this Warrant and payment of the
         aggregate  Exercise Price in effect  immediately  prior to such action,
         the kind and amount of shares and other  securities  and property which
         it  would  have  owned or have  been  entitled  to  receive  after  the
         happening  of  such   transaction   had  this  Warrant  been  exercised
         immediately prior thereto, subject to further adjustment as provided in
         Section 12.

12.      ADJUSTMENTS OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES.

         The number of and kind of securities  purchasable upon exercise of this
         Warrant and the Exercise Price shall be subject to adjustment from time
         to time as set forth in this Section 12.

         (a)      SUBDIVISIONS,  COMBINATIONS,  STOCK DIVIDENDS, SALES AND OTHER
                  ISSUANCES.  If at any time after the date hereof,  the Company
                  shall  issue  shares  of  Common  Stock  or  rights,  options,
                  warrants  or other  securities  to  subscribe  for or purchase
                  Common Stock, or securities convertible or exercisable into or
                  exchangeable  for Common Stock  ("COMMON  STOCK  EQUIVALENTS")
                  (excluding shares, rights,  options,  warrants, or convertible
                  or  exchangeable  securities,  issued  or  issuable  (i)  upon
                  exercise of the Warrants or any other Common Stock Equivalents
                  outstanding  as of the date hereof,  or issuable in connection
                  with the Company's  Series A Preferred  Stock  offering , (ii)
                  upon  conversion  of the Series A Preferred  Stock,  par value
                  $0.01  per  share,  of  the  Company,  (iii)  pursuant  to the
                  exercise   of  any  stock   options  or   warrants   currently
                  outstanding  or  options  or  warrants  issued  after the date
                  hereof  pursuant to any Company  benefit  plan,  stock  option
                  plan, stock bonus plan or other equity program approved by the
                  Company's  Board of  Directors,  but only to the extent,  that
                  such shares of Common  Stock  issued or  issuable  pursuant to
                  such stock option plans,  stock bonus plans or stock incentive
                  plans  does  not  exceed  ten   percent   (10%)  of  the  then
                  outstanding  Common Stock on a fully diluted basis, (iv) a one
                  time  issuance  of  up  to  $2,000,000  in  additional  equity
                  securities  during the twelve (12) month period  following the
                  final  closing date of the  Offering at a purchase  price less
                  than the  applicable  conversion  price  with  respect  to the
                  Series A  Preferred  or (v) with  respect to any  issuance  or
                  transaction  as to  which  holders  of a  66-2/3%  of the then

<PAGE>

                  outstanding  shares of the Company's Series A Preferred Stock,
                  par value  $0.001  per  share,  have  provided  prior  written
                  consent),  at a price per share lower than the Exercise  Price
                  per share of Common Stock in effect  immediately prior to such
                  issuance, then the Exercise Price shall be reduced on the date
                  of such issuance to a price  (calculated  to the nearest cent)
                  determined  by  multiplying   the  Exercise  Price  in  effect
                  immediately  prior to such  issuance  by a  fraction,  (1) the
                  numerator  of which shall be an amount equal to the sum of (A)
                  the number of shares of Common Stock on a fully  diluted basis
                  (assuming conversion, exchange or exercise of all Common Stock
                  Equivalents)  immediately  prior to such issuance plus (B) the
                  quotient  obtained by dividing the  consideration  received by
                  the Company upon such issuance by the Exercise Price,  and (2)
                  the  denominator  of which shall be the total number of shares
                  of Common Stock on a fully diluted basis (assuming conversion,
                  exchange  or  exercise  of  all  Common   Stock   Equivalents)
                  immediately  after such  issuance.  For the  purposes  of such
                  adjustments, the maximum number of shares which the holders of
                  any  such  Common  Stock  Equivalents  shall  be  entitled  to
                  subscribe   for  or  purchase  or  convert  or  exchange  such
                  securities  into shall be deemed to be issued and  outstanding
                  as of the date of such  issuance  (whether  or not such Common
                  Stock   Equivalent  is  then   exercisable,   convertible   or
                  exchangeable),  and the consideration  received by the Company
                  therefor shall be deemed to be the  consideration  received by
                  the  Company  for  such  Common  Stock  Equivalents,  plus the
                  minimum  aggregate  consideration  or premiums  stated in such
                  Common Stock  Equivalents,  to be paid for the shares  covered
                  thereby.  No further adjustment of the Exercise Price shall be
                  made as a result of the  actual  issuance  of shares of Common
                  Stock on  exercise of such Common  Stock  Equivalents.  On the
                  expiration   or  the   termination   of  such   Common   Stock
                  Equivalents,  or the  termination  of such right to convert or
                  exchange,  the Exercise  Price shall  forthwith be  readjusted
                  (but only with respect to that  portion of the Warrants  which
                  has not yet been  exercised) to such  Exercise  Price as would
                  have  obtained had the  adjustments  made upon the issuance of
                  such Common Stock Equivalents, been made upon the basis of the
                  delivery of only the number of shares of Common Stock actually
                  delivered upon the exercise of such Common Stock  Equivalents;
                  and on any  change of the  number  of  shares of Common  Stock
                  deliverable  upon  the  exercise  of  any  such  Common  Stock
                  Equivalents, or any change in the consideration to be received
                  by the Company upon such  exercise,  conversion,  or exchange,
                  including,  but not  limited to, a change  resulting  from the
                  anti-dilution  provisions thereof, the Exercise Price, as then
                  in  effect,  shall  forthwith  be  readjusted  (but  only with
                  respect to that portion of the Warrants which has not yet been
                  exercised  or converted  after such  change) to such  Exercise
                  Price as would have been obtained had an adjustment  been made
                  upon  the  issuance  of  such  Common  Stock  Equivalents  not
                  exercised prior to such change, or securities not converted or
                  exchanged  prior to such change,  on the basis of such change.
                  In the event of any  adjustment in the Exercise Price pursuant
                  to this Section 12(a),  the number of Warrant Shares  issuable
                  hereunder  upon  exercise  shall be inversely  proportionately
                  increased or decreased as the case may be, such that aggregate
                  purchase  price for Warrant  Shares upon full exercise of this
                  Warrant shall remain the same.

         (b)      MERGER,  ETC. If at any time after the date hereof there shall
                  be a merger or  consolidation of the Company with or into or a
                  transfer of all or substantially all of

<PAGE>

                  the assets of the Company to another  entity,  then the Holder
                  shall be  entitled  to receive  upon or after  such  transfer,
                  merger or consolidation  becoming effective,  and upon payment
                  of the Exercise Price then in effect,  the number of shares or
                  other  securities  or  property  of  the  Company  or  of  the
                  successor   corporation   resulting   from   such   merger  or
                  consolidation,  which  would have been  received by the Holder
                  for the  shares  of stock  subject  to this  Warrant  had this
                  Warrant been exercised just prior to such transfer,  merger or
                  consolidation  becoming  effective or to the applicable record
                  date  thereof,  as the case may be. The Company will not merge
                  or consolidate with or into any other corporation,  or sell or
                  otherwise   transfer   its   property,   assets  and  business
                  substantially  as an entirety to another  corporation,  unless
                  the  corporation  resulting from such merger or  consolidation
                  (if not the Company), or such transferee  corporation,  as the
                  case may be,  shall  expressly  assume in writing  the due and
                  punctual performance and observance of each and every covenant
                  and  condition of this Warrant to be performed and observed by
                  the Company.

         (c)      RECLASSIFICATION,  ETC.  If at any time after the date  hereof
                  there shall be a  reorganization  or  reclassification  of the
                  securities  as to which  purchase  rights  under this  Warrant
                  exist into the same or a different number of securities of any
                  other class or classes,  then the Holder shall  thereafter  be
                  entitled to receive upon exercise of this Warrant,  during the
                  period specified herein and upon payment of the Exercise Price
                  then in effect,  the number of shares or other  securities  or
                  property    resulting    from    such     reorganization    or
                  reclassification, which would have been received by the Holder
                  for the  shares  of stock  subject  to this  Warrant  had this
                  Warrant at such time been exercised.

         (d)      For the purposes of the foregoing adjustments,  in the case of
                  the issuance of any convertible securities (including, without
                  limitation,  shares of  Series A  Preferred  Stock)  warrants,
                  options or other  rights to  subscribe  for or to  purchase or
                  exchange   for,   shares   of   Common   Stock   ("CONVERTIBLE
                  SECURITIES"),  the  maximum  number of shares of Common  Stock
                  issuable  upon  exercise,   exchange  or  conversion  of  such
                  Convertible  Securities  shall be  deemed  to be  outstanding,
                  provided  that no  further  adjustment  shall be made upon the
                  actual  issuance of Common  Stock upon  exercise,  exchange or
                  conversion of such Convertible Securities. Upon the expiration
                  of any such  Convertible  Securities or the termination of any
                  such right to convert or exchange such Convertible Securities,
                  the Conversion  Price then in effect hereunder shall forthwith
                  be increased to the Conversion  Price which would have been in
                  effect at the time of such  expiration or termination had such
                  Convertible Securities,  to the extent outstanding immediately
                  prior to such  expiration or  termination,  never been issued,
                  and the Common Stock  issuable  thereunder  shall no longer be
                  deemed to be outstanding.

         (e)      In the event of any adjustment in the number of Warrant Shares
                  issuable hereunder upon exercise,  the Exercise Price shall be
                  inversely  proportionately  increased or decreased as the case
                  may be, such that aggregate  purchase price for Warrant Shares
                  upon full  exercise  of this  Warrant  shall  remain the same.
                  Similarly,  in the  event of any  adjustment  in the  Exercise
                  Price, the number of Warrant Shares issuable

<PAGE>

                  hereunder  upon  exercise  shall be inversely  proportionately
                  increased or decreased as the case may be, such that aggregate
                  purchase  price for Warrant  Shares upon full exercise of this
                  Warrant shall remain the same.

13.      VOLUNTARY  ADJUSTMENT BY THE COMPANY. The Company may at its option, at
         any time during the term of this  Warrant,  reduce but not increase the
         then  current  Exercise  Price to any amount and for any period of time
         deemed appropriate by the Board of Directors of the Company.

14.      MANDATORY REDEMPTION. Notwithstanding anything to the contrary provided
         herein,  this  Warrant  may be redeemed by the Company for a payment of
         $0.001 per  Warrant  Share  upon  written  notice to the Holder  within
         thirty (30) days after the Company has provided  written  notice to the
         Holder  that (i) the Common  Stock has  achieved a thirty  Trading  Day
         trailing  average  trading price per share on the  principal  market on
         which such shares are traded  equal to or greater  than three (3) times
         the then current  Exercise  Price and (ii) such shares are traded at an
         average  daily  volume of no less than  40,000  shares  during the same
         thirty  (30)  day  trading   period,   provided  that,  this  mandatory
         redemption  right will only be exercisable by the Company if the Common
         Stock for which this Warrant is  exercisable is subject to an effective
         registration  statement  relating to the resale of such common stock at
         the time of such mandatory redemption.

15.      NOTICE OF  ADJUSTMENT.  Whenever the number of Warrant Shares or number
         or kind of securities or other property  purchasable  upon the exercise
         of this Warrant or the Exercise  Price is adjusted,  the Company  shall
         promptly mail to the Holder of this Warrant a notice  setting forth the
         number of Warrant Shares (and other securities or property) purchasable
         upon  the  exercise  of this  Warrant  and the  Exercise  Price of such
         Warrant Shares after such  adjustment and setting forth the computation
         of such  adjustment and a brief  statement of the facts  requiring such
         adjustment.

16.      AUTHORIZED  SHARES.  The Company  covenants  that during the period the
         Warrant  is  outstanding  and  exercisable,  it will  reserve  from its
         authorized and unissued  Common Stock a sufficient  number of shares to
         provide for the issuance of the Warrant Shares upon the exercise of any
         and all  purchase  rights  under  this  Warrant.  The  Company  further
         covenants  that its  issuance of this  Warrant  shall  constitute  full
         authority  to its  officers  who are charged with the duty of executing
         stock certificates to execute and issue the necessary  certificates for
         the Warrant Shares upon the exercise of the purchase  rights under this
         Warrant.  The Company  will take all such  reasonable  action as may be
         necessary to assure that such Warrant  Shares may be issued as provided
         herein without violation of any applicable law, regulation,  or rule of
         any applicable market or exchange.

17.      COMPLIANCE  WITH  SECURITIES  LAWS. (a) The Holder hereof  acknowledges
         that the Warrant Shares acquired upon the exercise of this Warrant,  if
         not registered (or if no exemption from registration exists), will have
         restrictions upon resale imposed by state and federal  securities laws.
         Each  certificate  representing the Warrant Shares issued to the Holder
         upon exercise (if not  registered,  for resale or  otherwise,  or if no
         exemption  from  registration   exists)  will  bear  substantially  the
         following legend:

         THE SHARES  REPRESENTED BY THIS  CERTIFICATE  HAVE NOT BEEN  REGISTERED
         WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE

<PAGE>

         SECURITIES  COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION  FROM
         REGISTRATION  UNDER  THE  SECURITIES  ACT  OF  1933,  AS  AMENDED  (THE
         "SECURITIES ACT"), AND, ACCORDINGLY,  MAY NOT BE OFFERED,  TRANSFERRED,
         SOLD  OR  OTHERWISE   DISPOSED  OF  EXCEPT  PURSUANT  TO  AN  EFFECTIVE
         REGISTRATION  STATEMENT  UNDER THE  SECURITIES  ACT OR  PURSUANT  TO AN
         AVAILABLE  EXEMPTION  FROM,  OR IN A  TRANSACTION  NOT  SUBJECT TO, THE
         REGISTRATION  REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
         APPLICABLE STATE SECURITIES LAWS.

(b)      Without limiting the Purchaser's right to transfer, assign or otherwise
         convey the Warrant or Warrant Shares in compliance  with all applicable
         securities  laws,  the Holder of this Warrant,  by  acceptance  hereof,
         acknowledges that this Warrant and the Warrant Shares to be issued upon
         exercise  hereof  are being  acquired  solely for the  Purchaser's  own
         account  and not as a  nominee  for  any  other  party,  and  that  the
         Purchaser will not offer,  sell or otherwise dispose of this Warrant or
         any  Warrant  Shares to be issued upon  exercise  hereof  except  under
         circumstances that will not result in a violation of applicable federal
         and state securities laws.

18.      MISCELLANEOUS.

(a)      ISSUE DATE; CHOICE OF LAW; VENUE; JURISDICTION.  The provisions of this
         Warrant shall be construed and shall be given effect in all respects as
         if it had been issued and  delivered by the Company on the date hereof.
         This  Warrant  shall be binding upon any  successors  or assigns of the
         Company. This Warrant will be construed and enforced in accordance with
         and  governed by the laws of the State of New York,  except for matters
         arising under the Act, without  reference to principles of conflicts of
         law. Each of the parties consents to the exclusive  jurisdiction of the
         Federal and State Courts sitting in the County of New York in the State
         of New York in connection  with any dispute  arising under this Warrant
         and  hereby  waives,  to the  maximum  extent  permitted  by  law,  any
         objection,  including  any objection  based on FORUM NON  CONVENIENS or
         venue,  to the bringing of any such  proceeding  in such  jurisdiction.
         EACH PARTY HERETO WAIVES THE RIGHT TO A TRIAL BY JURY.

(b)      MODIFICATION AND WAIVER.  This Warrant and any provisions hereof may be
         changed,  waived,  discharged  or  terminated  only by an instrument in
         writing  signed by the party against which  enforcement  of the same is
         sought.  Any amendment effected in accordance with this paragraph shall
         be binding upon the  Purchaser,  each future holder of this Warrant and
         the Company.  No waivers of, or exceptions  to, any term,  condition or
         provision  of this  Warrant,  in any one or more  instances,  shall  be
         deemed to be, or construed  as, a further or  continuing  waiver of any
         such term, condition or provision.

(c)      NOTICES. Any notice or other communication  required or permitted to be
         given  hereunder  shall be in writing by  facsimile,  mail or  personal
         delivery and shall be effective upon actual receipt of such notice. The
         addresses for such communications shall be to the addresses as shown on
         the books of the  Company or to the Company at the address set forth in
         the  Subscription  Agreement.  A party may from time to time change the
         address

<PAGE>

         to which  notices  to it are to be  delivered  or mailed  hereunder  by
         notice in accordance with the provisions of this Section 18(c).

(d)      SEVERABILITY.  Whenever possible,  each provision of this Warrant shall
         be  interpreted  in such  manner as to be  effective  and  valid  under
         applicable  law,  but if any  provision  of this  Warrant is held to be
         invalid,  illegal or  unenforceable in any respect under any applicable
         law or  rule  in  any  jurisdiction,  such  invalidity,  illegality  or
         unenforceability   shall  not  affect   the   validity,   legality   or
         enforceability   of  any  other  provision  of  this  Warrant  in  such
         jurisdiction or affect the validity,  legality or enforceability of any
         provision  in  any  other  jurisdiction,  but  this  Warrant  shall  be
         reformed,  construed  and  enforced  in  such  jurisdiction  as if such
         invalid,  illegal or  unenforceable  provision had never been contained
         herein.

(e)      SPECIFIC ENFORCEMENT.  The Company and the Holder acknowledge and agree
         that  irreparable  damage  would  occur  in the  event  that any of the
         provisions of this Warrant were not performed in accordance  with their
         specific terms or were  otherwise  breached.  It is accordingly  agreed
         that the parties shall be entitled to an injunction or  injunctions  to
         prevent or cure  breaches  of the  provisions  of this  Warrant  and to
         enforce  specifically  the terms and provisions  hereof,  this being in
         addition to any other remedy to which either of them may be entitled by
         law or equity.

                            [SIGNATURE PAGE FOLLOWS]

<PAGE>

         IN WITNESS WHEREOF,  the Company has caused this Warrant to be executed
by its officers thereunto duly authorized.
Dated:  ________, 2005

                                              BIONUTRICS, INC.

                                              By: ______________________________
                                                  Name:
                                                  Title:

ATTEST:

________________________
Print Name:

<PAGE>

                               NOTICE OF EXERCISE

To:      Bionutrics, Inc.

(1)      The undersigned  hereby elects to exercise the attached Warrant for and
to purchase  thereunder,  ______  shares of Common  Stock,  and  herewith  makes
payment therefor of $_______.

(2)      Please issue a certificate or certificates  representing said shares of
Common  Stock  in the  name  of the  undersigned  or in  such  other  name as is
specified below:

                           _______________________________
                           (Name)

                           _______________________________
                           (Address)

                           _______________________________

(3)      Please issue a new Warrant for the unexercised  portion of the attached
Warrant in the name of the  undersigned  or in such  other name as is  specified
below:

                                             ___________________________________
                                             (Name)

____________________                         ___________________________________
(Date)                                       (Signature)

                                             ___________________________________
                                             (Address)

Dated:

_____________________________
Signature

<PAGE>

                                 ASSIGNMENT FORM

                    (To assign the foregoing warrant, execute
                   this form and supply required information.
                 Do not use this form to exercise the warrant.)

                  FOR VALUE  RECEIVED,  the  foregoing  Warrant  and all  rights
evidenced thereby are hereby assigned to

_______________________________________________ whose address is

__________________________________________________________________.

__________________________________________________________________

                                                    Dated:  ______________,

                      Holder's Signature:       ___________________________

                      Holder's Address:         ___________________________

                                                ___________________________

Signature Guaranteed:  __________________________________

NOTE: The signature to this  Assignment Form must correspond with the name as it
appears on the face of the Warrant,  without  alteration or  enlargement  or any
change whatsoever,  and must be guaranteed by a bank or trust company.  Officers
of corporations and those acting in a fiduciary or other representative capacity
should file proper evidence of authority to assign the foregoing Warrant.Exhibit 10.6

                               AMENDMENT NO. 3 TO
                          TECHNOLOGY LICENSE AGREEMENT

         Amendment No. 3 to Technology License Agreement (the "Agreement") dated
as of March 16,  2005,  as amended  June 30,  2005 and August 25,  2005,  by and
between  Nostrum  Pharmaceuticals,   Inc.  ("Nostrum"),   and  Bionutrics,  Inc.
("Bionutrics") is made and entered into this 3rd day of October, 2005.

         WHEREAS,  Bionutrics  has or is to enter into certain  agreements  with
several  financial  organizations  to raise funds for Bionutrics to acquire Kirk
Pharmaceuticals  LLC, finance product  development by Nostrum,  and fund general
corporate  expenses,  and those  organizations  require that  Nostrum  waive its
rights to terminate the Agreement,  as provided in Section 9.3 thereof, in order
for them to agree to proceed with the financings; and

         WHEREAS,  Nostrum has indicated a willingness  to waive those rights in
consideration of Bionutrics' assumption and discharge of $1.5 million in respect
of Nostrum's  obligation to pay Enem Nostrum Remedies Pvt. Ltd. ("Enem") for its
work in the  development of certain  pharmaceutical  products for which Enem has
previously submitted invoices which have been given to Bionutrics;

         NOW, THEREFORE, in consideration of these agreements and other good and
valuable  consideration,  the  receipt  and  sufficiency  of  which  are  hereby
acknowledged, the parties agree, as follows:

         1.       Nostrum  agrees to waive each and every  right of  termination
                  set forth in Section 9.3 of the Agreement.

         2.       The  Agreement is hereby  amended by deleting  each of Section
                  9.3 and Section 9.6(a) in their respective entireties from the
                  Agreement and substituting therefor the word "Reserved."

         3.       Section  9.6(b) of the Agreement is hereby  amended to read as
                  follows:

                  (b) In the event that this Agreement is terminated pursuant to
                  Section  9.2,  9.4 or 9.5 with  respect  to one or more of the
                  Products  hereunder,  (i) the  license  granted to  Bionutrics
                  under  Section  2.1  shall   terminate  with  respect  to  the
                  Product(s) that are the subject of the  termination;  and (ii)
                  Bionutrics   shall   transfer   to  Nostrum  all  of  (a)  the
                  Formulations,  processes and other technology relating to such
                  Product(s);  (b)  the  approvals  and  applications  for  such
                  Product(s) (except any NDAs or ANDAs which Bionutrics obtained
                  hereunder for such  Product(s)),  and (c) the records directly
                  related  to  the  development  and  commercialization  of  the
                  Product(s);  and (iii) Nostrum shall thereafter have the right
                  to  develop,

<PAGE>

                  manufacture and otherwise commercialize such Product(s) in the
                  Territory.

         IN WITNESS WHEREOF,  the parties have executed this Agreement as of the
date first set forth above.

NOSTRUM PHARMACEUTICALS, INC.              BIONUTRICS, INC.

By:                                        By:
    ______________________________             ______________________________
      Nirmal Mulye, Ph.D.                         Ronald Howard Lane, Ph.D.
      President                                   Chairman, CEO and President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]